Atezolizumab and bevacizumab with optional repeat chemo liver procedure
Part of Cancer clinical trials.
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatocellular carcinoma (HCC), a specific type of liver cancer
- Your cancer cannot be cured by surgery or local “spot” treatments, but it is eligible for TACE
- You are age 18 or older and can follow the study plan
- Your overall health is good (ECOG 0–1) and you have enough liver function (Child-Pugh A or B7)
- Your screening tests look okay (negative HIV, and blood/organ tests meet study needs)
- Your cancer doesn’t have certain high-risk features (like diffuse disease, major spread, too many lesions, very large tumors, or tumor-vessel invasion)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.